Comprehensive Analysis for Histone Acetylation of Human Colon Cancer Cells Treated with a novel HDAC Inhibitor

Abstract

Extensive evidence suggests that dysregulation of histone lysine acetylation is intimately linked with the development of cancer in epigenetic level. Histone acetylation on lysine is regulated mainly by the "pencil"--Histone acetyltransferases (HATs) and the "eraser"--Histone deacetylases HDACs. Dramatic elevation of global histone deacetylation is considered as a biomarker for cancer. Therefore, current antitumor drug design often targets HDACs, inhibiting overexpressed HDAC in tumor cells with natural or synthesized small molecules like largazole. Recently, a novel largazole derivative (largazole-7) was designed and prepared by replacement of Val 1 with tyrosine, and this modification increases selectivity toward human cancer cells over normal cells more than 100-fold. However, it is unclear about the dynamic level of histone acetylation under the treatment of this drug. It is also unclear whether the other modifications are also affected by largazole-7 treatment. Therefore, a global mapping of modifications on the histone proteins of cancer cell line treated by this drug may be of great benefit to elucidating its molecular mechanisms and exploring its potent as an antitumor drug. To realize the goal, we combined stable isotope labeling by amino acids in cell culture (SILAC) and high resolution MS for comprehensive identification and quantitative analysis of histone lysine acetylation and other modifications of Human Colon Cancer Cells (HCT-116) with and without treatment of largazole-7. In this analysis, we identified 68 histone PTMs in 38 sites on core histones, including lysine acetylation, methylation and butyrylation, a novel lysine modification. Further quantitative analysis not only discovered the global increased acetylated lysines, but also observed the changes of abundance of lysine methylation and butyrylation under stimulation of the drug. To our knowledge, it is the first report that regulation of largazole-7 against lysine butyrylation. Our study expands the catalog of histone marks in cancer, and provides an approach for understanding the known and new epigenetic marks under treatment of drugs.

Analyzing epigenetic control of galectin expression indicates silencing of galectin‐12 by promoter methylation in colorectal cancer

“…Epigenetic instability manifested as aberrant DNA methylation is observed in essentially all CRCs . Likewise, dysregulation of lysine acetylation in histones is intimately linked with the development of CRC and its metastasis . According to the epigenetic progenitor model of cancer epigenetic alterations affecting tissue specific differentiation are the prominent mechanism by which epigenetic changes cause cancer .…”

Advances of Proteomics in Novel PTM Discovery: Applications in Cancer Therapy

“…A proteomic study showed that the inhibition of Hsp90 in bladder cancer significantly affected the propionylation and butyrylation of core histones . Largazole‐7, a novel largazole derivative, was reported to alter the abundance of lysine methylation and butyrylation in histones, suggesting that targeting histone PTMs is a potential strategy for cancer therapy.…”

Screening for Colorectal Cancer Leading into a New Decade: The “Roaring ‘20s” for Epigenetic Biomarkers?

“…These can happen in different amino acid residues at several positions, although they are most common at histone N-terminal tails [ 29 , 30 ]. Mounting evidence suggests that aberrant histone lysine acetylation is a critical epigenetic driver of malignant transformation [ 31 , 32 ]. Histone lysine acetylation is regulated mostly by Histone acetyltransferases (HATs) and Histone deacetylases (HDACs).…”